targets for optimal synergy between localised therapies and ICB. Here, we review studies on the immunomodulatory eklects of novel and experilkntal localised therapies, as well as the re-evaluation of established therapies, such as radiotherapy, as immune adjuvants with a focus on ICPI combinations.Cancer immunotherapies, particularly immune
targets for optimal synergy between localised therapies and ICB. Here, we review studies on the immunomodulatory eklects of novel and experilkntal localised therapies, as well as the re-evaluation of established therapies, such as radiotherapy, as immune adjuvants with a focus on ICPI combinations.Cancer immunotherapies, particularly immune